Susan Bobulsky's Insider Trades & SAST Disclosures
Susan Bobulsky's most recent trade in Adaptive Biotechnologies Corp was a trade of 180,029 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Susan Bobulsky.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corp | Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 180,029 | 180,029 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 119,971 | 373,261 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 26,023 | 347,238 (0%) | 0% | 7.0 | 181,641 | Common Stock |
| Adaptive Biotechnologies Corp | Susan Bobulsky | Chief Commercial Officer, MRD | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2024 | 5,000 | 0 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Susan Bobulsky | Chief Commercial Officer, MRD | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 08 Oct 2024 | 5,000 | 253,290 (0%) | 0% | 2.0 | 9,900 | Common Stock |
| Adaptive Biotechnologies Corp | Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 199,549 | 199,549 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 132,979 | 261,281 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 3.44 per share. | 04 Mar 2024 | 6,975 | 248,290 (0%) | 0% | 3.4 | 23,994 | Common Stock |
| Adaptive Biotechnologies Corp | Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 6,016 | 255,265 (0%) | 0% | 3.4 | 20,635 | Common Stock |
| Adaptive Biotechnologies Corp | Susan Bobulsky | SVP, Diagnostics, clonoSEQ | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 22,894 | 22,894 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Susan Bobulsky | SVP, Diagnostics, clonoSEQ | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 9,158 | 9,158 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Susan Bobulsky | SVP, Diagnostics, clonoSEQ | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Sep 2020 | 10,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Susan Bobulsky | SVP, Diagnostics, clonoSEQ | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 29 Sep 2020 | 10,000 | 0 (0%) | 0% | 50 | 500,000 | Common Stock |
| Adaptive Biotechnologies Corp | Susan Bobulsky | SVP, Diagnostics, clonoSEQ | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 29 Sep 2020 | 10,000 | 10,000 (0%) | 0% | 2.0 | 19,800 | Common Stock |
| Adaptive Biotechnologies Corp | Susan Bobulsky | SVP, Diagnostics, clonoSEQ | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2020 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges